Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.75 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 12/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ACP1 | P24666 | 2/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20339606 | 1.00 | NLRP3 (0.75) | NLRP3DUSP22PTPN1ENPP2MEN1 | |
| SCHEMBL20339998 | 0.92 | NLRP3 (0.81) | NLRP3DUSP22PTPN1MEN1KMT2A | |
| SCHEMBL20340001 | 0.92 | NLRP3 (0.81) | NLRP3DUSP22PTPN1MEN1KMT2A | |
| SCHEMBL20339359 | 0.83 | NLRP3 (0.61) | NLRP3DUSP22PTPN1ENPP2PTPN2 | |
| SCHEMBL20339662 | 0.83 | NLRP3 (0.61) | NLRP3DUSP22PTPN1ENPP2PTPN2 | |
| SCHEMBL20339361 | 0.83 | NLRP3 (0.61) | NLRP3DUSP22PTPN1ENPP2PTPN2 | |
| SCHEMBL20348907 | 0.82 | MEN1 (0.66) | NLRP3DUSP22PTPN1ENPP2MEN1 | |
| SCHEMBL12177336 | 0.82 | PTPN1 (0.74) | NLRP3PTPN1ENPP2ACP1PTPN2 | |
| SCHEMBL20339740 | 0.81 | NLRP3 (0.61) | NLRP3DUSP22PTPN1ENPP2PTPN2 | |
| SCHEMBL20339741 | 0.81 | NLRP3 (0.61) | NLRP3DUSP22PTPN1ENPP2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | GB006 INC (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2018126072-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ADHAERE PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ITGA1, ITGA4, ITGA2 | NLRP3 1510/4885DUSP22 3787/4885PTPN1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.